2.22
price up icon2.30%   0.05
after-market アフターアワーズ: 2.15 -0.07 -3.15%
loading
前日終値:
$2.17
開ける:
$2.18
24時間の取引高:
1.21M
Relative Volume:
2.35
時価総額:
$159.46M
収益:
$31.25M
当期純損益:
$-88.48M
株価収益率:
-1.4323
EPS:
-1.55
ネットキャッシュフロー:
$-79.63M
1週間 パフォーマンス:
+29.82%
1か月 パフォーマンス:
+86.55%
6か月 パフォーマンス:
+63.24%
1年 パフォーマンス:
-58.66%
1日の値動き範囲:
Value
$2.15
$2.31
1週間の範囲:
Value
$1.65
$2.31
52週間の値動き範囲:
Value
$0.5902
$5.705

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
名前
Aclaris Therapeutics Inc
Name
セクター
Healthcare (1182)
Name
電話
484-324-7933
Name
住所
701 LEE ROAD, WAYNE, PA
Name
職員
91
Name
Twitter
@aclaristx
Name
次回の収益日
2024-11-18
Name
最新のSEC提出書
Name
ACRS's Discussions on Twitter

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-12-14 開始されました Stifel Buy
2022-12-01 開始されました Goldman Buy
2022-10-06 開始されました BTIG Research Buy
2021-07-23 再開されました Jefferies Buy
2021-06-15 開始されました Piper Sandler Overweight
2021-04-21 開始されました H.C. Wainwright Buy
2019-10-22 アップグレード SVB Leerink Mkt Perform → Outperform
2019-09-06 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2019-06-27 ダウングレード SVB Leerink Outperform → Mkt Perform
2019-05-06 開始されました SVB Leerink Outperform
2018-03-28 再開されました Leerink Partners Outperform
2018-02-09 開始されました Guggenheim Buy
2017-06-16 開始されました Cantor Fitzgerald Overweight
2016-11-29 開始されました Leerink Partners Outperform
2016-09-30 開始されました JMP Securities Mkt Outperform
2016-06-10 開始されました Guggenheim Buy
2015-11-02 開始されました Citigroup Buy
2015-11-02 開始されました Jefferies Buy
すべてを表示

Aclaris Therapeutics Inc (ACRS) 最新ニュース

pulisher
Oct 30, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Shares Cross Above 50-Day Moving AverageWhat's Next? - MarketBeat

Oct 26, 2024
pulisher
Oct 20, 2024

Contrasting Star Equity (NASDAQ:STRR) and Aclaris Therapeutics (NASDAQ:ACRS) - Defense World

Oct 20, 2024
pulisher
Oct 09, 2024

Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Oct 08, 2024
pulisher
Oct 07, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLC - MarketBeat

Oct 07, 2024
pulisher
Oct 05, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Target Price from Analysts - MarketBeat

Oct 05, 2024
pulisher
Oct 01, 2024

Stonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat

Oct 01, 2024
pulisher
Sep 23, 2024

Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily

Sep 23, 2024
pulisher
Sep 21, 2024

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MSN

Sep 21, 2024
pulisher
Sep 21, 2024

Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo

Sep 21, 2024
pulisher
Sep 18, 2024

AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch

Sep 18, 2024
pulisher
Sep 18, 2024

Accenture (NYSE:ACN) PT Raised to $365.00 - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Investing in Astrazeneca plc ADR (AZN) Is Getting More Attractive - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha

Sep 18, 2024
pulisher
Sep 18, 2024

Metric Deep Dive: Understanding Accenture plc (ACN) Through its Ratios - The Dwinnex

Sep 18, 2024
pulisher
Sep 18, 2024

American Century Companies Inc. Boosts Stock Position in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial - Clinical Trials Arena

Sep 18, 2024
pulisher
Sep 18, 2024

Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

Accel Entertainment CEO sells shares worth over $49,000 By Investing.com - Investing.com UK

Sep 17, 2024
pulisher
Sep 17, 2024

Arch Capital Group (ACGL) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance

Sep 17, 2024
pulisher
Sep 17, 2024

AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch

Sep 17, 2024
pulisher
Sep 17, 2024

Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Meeder Advisory Services Inc. Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

William Blair Investment Management LLC Sells 17,390 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Receives "Neutral" Rating from HC Wainwright - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Arch Capital Group (NASDAQ:ACGL) Sets New 1-Year High at $114.69 - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

(ACEL) Long Term Investment Analysis - Stock Traders Daily

Sep 17, 2024
pulisher
Sep 17, 2024

Analyzing Axcelis Technologies Inc (ACLS) After Recent Trading Activity - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

Quest Partners LLC Cuts Stake in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Financial Metrics Exploration: Understanding Acrivon Therapeutics Inc (ACRV) Through Ratios - The Dwinnex

Sep 17, 2024
pulisher
Sep 17, 2024

Market Watch: Aclarion Inc (ACON)’s Noteworthy Drop, Closing at 0.18 - The Dwinnex

Sep 17, 2024
pulisher
Sep 17, 2024

Citi lifts Accenture stock price target on growth prospects - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Analysts - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Aclaris Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire

Sep 17, 2024
pulisher
Sep 17, 2024

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis - Yahoo Finance

Sep 17, 2024
pulisher
Sep 17, 2024

Quest Partners LLC Grows Position in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World

Sep 17, 2024
pulisher
Sep 16, 2024

Arch Capital Group (ACGL) Outperforms Broader Market: What You Need to Know - Yahoo Finance

Sep 16, 2024
pulisher
Sep 16, 2024

Accenture (ACN) Rises Higher Than Market: Key Facts - Yahoo Finance

Sep 16, 2024
pulisher
Sep 16, 2024

AstraZeneca PLC ADR rises Monday, outperforms market - MarketWatch

Sep 16, 2024
pulisher
Sep 16, 2024

Market Momentum: Astrazeneca plc ADR (AZN) Registers a -0.87 Decrease, Closing at 78.27 - The Dwinnex

Sep 16, 2024
pulisher
Sep 16, 2024

Acrivon Therapeutics: Promising Trial Results and FDA Clearance - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

ICA Group Wealth Management LLC Decreases Stock Position in Accenture plc (NYSE:ACN) - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

ACADIA Pharmaceuticals (NASDAQ:ACAD) Lifted to Strong-Buy at StockNews.com - Defense World

Sep 16, 2024

Aclaris Therapeutics Inc (ACRS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Aclaris Therapeutics Inc (ACRS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Leonard Braden Michael
10% Owner
Aug 05 '24
Buy
1.24
206,025
256,357
14,250,000
Leonard Braden Michael
10% Owner
Aug 02 '24
Buy
1.29
167,544
216,400
14,043,975
Leonard Braden Michael
10% Owner
Jul 30 '24
Buy
1.30
173,730
226,370
13,776,421
Leonard Braden Michael
10% Owner
Jul 31 '24
Buy
1.33
100,000
132,640
13,876,421
Leonard Braden Michael
10% Owner
Jul 18 '24
Buy
1.30
130,317
169,555
13,578,286
Leonard Braden Michael
10% Owner
Jul 22 '24
Buy
1.33
17,716
23,557
13,602,691
Leonard Braden Michael
10% Owner
Jul 19 '24
Buy
1.30
6,689
8,696
13,584,975
Leonard Braden Michael
10% Owner
Jul 03 '24
Buy
1.16
143,288
166,071
13,324,952
Leonard Braden Michael
10% Owner
Jul 05 '24
Buy
1.15
123,017
141,334
13,447,969
Leonard Braden Michael
10% Owner
Jul 02 '24
Buy
1.14
86,092
98,489
13,181,664
$226.42
price up icon 3.48%
diagnostics_research LH
$229.11
price up icon 0.85%
diagnostics_research WAT
$387.17
price down icon 0.04%
$154.96
price up icon 0.96%
diagnostics_research MTD
$1,385.79
price up icon 1.60%
$415.98
price up icon 0.35%
大文字化:     |  ボリューム (24 時間):